Clinical Trials Browser

Phase 1/2 × Leukemia, Myeloid × gilteritinib × Clear all

NCT06235801 2025-11-19

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid